Supernus Pharmaceuticals | SUPN
Stock Price
36.84
Daily Change
-1.53 -3.99%
Monthly
-0.57%
Yearly
34.90%
Q1 Forecast
37.84



Peers Price Chg Day Year Date
Eisai 4,424.00 -197.00 -4.26% -35.21% Feb/03
Abbott 128.39 0.69 0.54% 12.14% Feb/03
Aurora Cannabis 5.06 -0.22 -4.17% -4.53% Feb/03
ANI Pharmaceuticals 57.96 -0.68 -1.16% 3.43% Feb/03
Bristol-Myers Squibb 59.76 0.89 1.51% 24.55% Feb/03
Corcept Therapeutics 67.41 0.49 0.73% 213.97% Feb/03
Indivior 942.50 -15.00 -1.57% -30.85% Feb/03
Eli Lilly 809.58 -1.59 -0.20% 22.58% Feb/03
Novo Nordisk A/S 599.70 -7.60 -1.25% -25.94% Feb/03
Pacira 26.18 -0.15 -0.57% -15.93% Feb/03
Pfizer 26.26 -0.24 -0.91% -3.77% Feb/03
Perrigo 25.12 0.26 1.03% -22.18% Feb/03
Supernus Pharmaceuticals 36.84 -1.53 -3.99% 34.90% Feb/03
United Therapeutics 356.78 5.61 1.60% 67.69% Feb/03
Canopy Growth 2.90 0.03 1.05% -51.99% Feb/03
Xeris Pharmaceuticals 3.60 0.04 1.12% 45.75% Feb/03

Indexes Price Day Year Date
USND 19446 -181.89 -0.93% 24.67% Feb/03
US2000 2261 -27.10 -1.18% 16.69% Feb/03

Supernus Pharmaceuticals traded at $36.84 this Monday February 3rd, decreasing $1.53 or 3.99 percent since the previous trading session. Looking back, over the last four weeks, Supernus Pharmaceuticals lost 0.57 percent. Over the last 12 months, its price rose by 34.90 percent. Looking ahead, we forecast Supernus Pharmaceuticals to be priced at 37.84 by the end of this quarter and at 36.30 in one year, according to Trading Economics global macro models projections and analysts expectations.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.